Abstract
BackgroundNumerous case–control studies have been performed to investigate the association between three cyclooxygenase-2 (COX-2) polymorphisms (rs20417 (−765G > C), rs689466 (−1195G > A), and rs5275 (8473 T > C)) and the risk of head and neck squamous cell carcinoma (HNSCC). However, the results were inconsistent. Therefore, we conducted this meta-analysis to investigate the association.MethodsWe searched in PubMed, Embase, and Web of Science up to January 20, 2015 (last updated on May 12, 2016). Two independent reviewers extracted the data. Odds ratios (ORs) with their 95 % confidence intervals (CIs) were used to assess the association. All statistical analyses were performed using the Review Manager (RevMan) 5.2 software.ResultsFinally 8 case–control studies were included in this meta-analysis. For unadjusted data, an association with increased risk was observed in three genetic models in COX-2 rs689466 polymorphism; however, COX-2 rs5275 and rs20417 polymorphisms were not related to HNSCC risk in this study. The pooled results from adjusted data all revealed non-significant association between these three polymorphisms and risk of HNSCC. We also found a similar result in the subgroup analyses, based on both unadjusted data and adjusted data.ConclusionCurrent results suggest that COX-2 rs689466, rs5275, and rs20417 polymorphisms are not associated with HNSCC. Further large and well-designed studies are necessary to validate this association.
Highlights
Numerous case–control studies have been performed to investigate the association between three cyclooxygenase-2 (COX-2) polymorphisms (rs20417 (−765G > C), rs689466 (−1195G > A), and rs5275 (8473 T > C)) and the risk of head and neck squamous cell carcinoma (HNSCC)
Eligibility criteria Cohort studies or case–control studies evaluating the risk of HNSCC in relation to COX-2 rs689466, rs5275, and/or rs20417 polymorphisms were considered for eligibility if they met the following criteria: (1) the cancer was HNSCC, oral squamous cell carcinoma (OSCC), or laryngeal squamous cell carcinoma (LSCC) confirmed using microscopic examination; (2) the frequency of genotype distribution, adjusted odds ratios (ORs) and their 95 % confidence intervals (CIs), or the data that can calculate them
5 case–control studies involving 1564 cases and 2346 controls focused on COX-2 rs689466 polymorphism [28, 30, 31, 33, 34], 4 studies involving 1259 cases and 2097 controls on COX-2 rs5275 polymorphism [27, 31, 33, 34], and 5 studies involving 1229 cases and 1164 controls on COX-2 rs20417 polymorphism [28,29,30,31,32]
Summary
Numerous case–control studies have been performed to investigate the association between three cyclooxygenase-2 (COX-2) polymorphisms (rs20417 (−765G > C), rs689466 (−1195G > A), and rs5275 (8473 T > C)) and the risk of head and neck squamous cell carcinoma (HNSCC). We conducted this meta-analysis to investigate the association. Head and neck squamous cell carcinoma (HNSCC) is 1 of the disease burdens worldwide affecting eating, breathing, and appearance. The association between COX-2 gene polymorphisms and risk of many cancers, such as hepatocellular carcinoma [16], colorectal cancer [17], breast cancer [18], prostate cancer [19], gastric cancer [20] were investigated by meta-analyses. The elevated expression of COX-2 was presented to be correlated with malignant transformation, advancing clinical stage, and disease progression [22]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
